Cargando…

Case Report: TEMPI syndrome: Report of three cases and treatment follow-up

The TEMPI syndrome is a novel and rare disease with five distinct clinical features: Telangiectasis, Erythrocytosis, Monoclonal gammopathy, Perinephric fluids collection, and Intrapulmonary shunting. Here, we report three cases of TEMPI syndrome and their treatment response. The three patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhuo-Fan, Ruan, Jing, Chang, Long, Wu, Sijin, Lin, Jinkai, Wang, Wei, Cao, XinXin, Zhang, Lu, Li, Jian, Zhou, Daobin, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382296/
https://www.ncbi.nlm.nih.gov/pubmed/35992844
http://dx.doi.org/10.3389/fonc.2022.949647
_version_ 1784769257631907840
author Xu, Zhuo-Fan
Ruan, Jing
Chang, Long
Wu, Sijin
Lin, Jinkai
Wang, Wei
Cao, XinXin
Zhang, Lu
Li, Jian
Zhou, Daobin
Zhang, Wei
author_facet Xu, Zhuo-Fan
Ruan, Jing
Chang, Long
Wu, Sijin
Lin, Jinkai
Wang, Wei
Cao, XinXin
Zhang, Lu
Li, Jian
Zhou, Daobin
Zhang, Wei
author_sort Xu, Zhuo-Fan
collection PubMed
description The TEMPI syndrome is a novel and rare disease with five distinct clinical features: Telangiectasis, Erythrocytosis, Monoclonal gammopathy, Perinephric fluids collection, and Intrapulmonary shunting. Here, we report three cases of TEMPI syndrome and their treatment response. The three patients were presented to our department with polycythemia, abdominal distension, and dyspnea. On admission, all patients manifested telangiectasis, erythrocytosis, monoclonal gammopathy, and intrapulmonary shunting. Patient 1 and 2 manifested perinephric fluids collection. In addition, all patients had skin pigmentation, patient 1 and 2 had polyserosal effusion, two symptoms that had not been associated with TEMPI syndrome before. The three patients showed various response to plasma cell-directed therapy. We demonstrated their treatment response by measuring erythropoietin, hemoglobin, and M protein levels throughout therapy. This report suggested that TEMPI syndrome is a rare yet treatable disease. The diagnosis and treatment of it remain challenging.
format Online
Article
Text
id pubmed-9382296
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93822962022-08-18 Case Report: TEMPI syndrome: Report of three cases and treatment follow-up Xu, Zhuo-Fan Ruan, Jing Chang, Long Wu, Sijin Lin, Jinkai Wang, Wei Cao, XinXin Zhang, Lu Li, Jian Zhou, Daobin Zhang, Wei Front Oncol Oncology The TEMPI syndrome is a novel and rare disease with five distinct clinical features: Telangiectasis, Erythrocytosis, Monoclonal gammopathy, Perinephric fluids collection, and Intrapulmonary shunting. Here, we report three cases of TEMPI syndrome and their treatment response. The three patients were presented to our department with polycythemia, abdominal distension, and dyspnea. On admission, all patients manifested telangiectasis, erythrocytosis, monoclonal gammopathy, and intrapulmonary shunting. Patient 1 and 2 manifested perinephric fluids collection. In addition, all patients had skin pigmentation, patient 1 and 2 had polyserosal effusion, two symptoms that had not been associated with TEMPI syndrome before. The three patients showed various response to plasma cell-directed therapy. We demonstrated their treatment response by measuring erythropoietin, hemoglobin, and M protein levels throughout therapy. This report suggested that TEMPI syndrome is a rare yet treatable disease. The diagnosis and treatment of it remain challenging. Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9382296/ /pubmed/35992844 http://dx.doi.org/10.3389/fonc.2022.949647 Text en Copyright © 2022 Xu, Ruan, Chang, Wu, Lin, Wang, Cao, Zhang, Li, Zhou and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xu, Zhuo-Fan
Ruan, Jing
Chang, Long
Wu, Sijin
Lin, Jinkai
Wang, Wei
Cao, XinXin
Zhang, Lu
Li, Jian
Zhou, Daobin
Zhang, Wei
Case Report: TEMPI syndrome: Report of three cases and treatment follow-up
title Case Report: TEMPI syndrome: Report of three cases and treatment follow-up
title_full Case Report: TEMPI syndrome: Report of three cases and treatment follow-up
title_fullStr Case Report: TEMPI syndrome: Report of three cases and treatment follow-up
title_full_unstemmed Case Report: TEMPI syndrome: Report of three cases and treatment follow-up
title_short Case Report: TEMPI syndrome: Report of three cases and treatment follow-up
title_sort case report: tempi syndrome: report of three cases and treatment follow-up
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382296/
https://www.ncbi.nlm.nih.gov/pubmed/35992844
http://dx.doi.org/10.3389/fonc.2022.949647
work_keys_str_mv AT xuzhuofan casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT ruanjing casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT changlong casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT wusijin casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT linjinkai casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT wangwei casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT caoxinxin casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT zhanglu casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT lijian casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT zhoudaobin casereporttempisyndromereportofthreecasesandtreatmentfollowup
AT zhangwei casereporttempisyndromereportofthreecasesandtreatmentfollowup